Research & Education

Immunotherapy for NSCLC: What's Next?

February 7, 2017 at 9:00PM EST - Recording Available



David Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, TN

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Name of Reviewer(s): 


Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose


Name of Activity: 


Immunotherapy for NSCLC: What's Next?

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members, reviewers, and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: David Spigel, MD

No relevant financial/commercials relationships to disclose.

Program Chair: Ramaswamy Govindan, MD-

Speakers or Advisory Board , Honoraria and consulting with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas; Honoraruim with the following: Baxalta, Roche

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

This presentation will provide an update on how immunotherapy has rapidly integrated into standard 1st and 2nd-Line and beyond treatment settings. We will also review and discuss:

  • the role of biomarker testing in clinical practice;
  • management of toxicity associated with immunotherapy;
  • immunotherapy treatment duration;
  • newer combinations of therapies;
  • and ongoing and planned pivotal trials.

After attending this program, participants will be able to:

  • recognize ongoing and planned  pivotal clinical trials of immunotherapy;
  • identify patients eligible for clinical trial participation;
  • specify immunotherapy for a select subset of patients likely to benefit.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Spigel via internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

In order to receive CME credit, attendees must fill out a program evaluation.

Financial/Commercial and Conflicts of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)


Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2017. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter